Want to see IN:ORTINGLOBE full AI Analyst Report?
ORTINGLOBE Stock Chart & Stats
₹11.55
₹0.54(3.15%)
At close: 4:00 PM EST
₹11.55
₹0.54(3.15%)
Day’s Range― - ―
52-Week Range₹11.18 - ₹21.15
Previous CloseN/A
Volume283.00
Average Volume (3M)4.53K
Market Cap
₹120.51M
Enterprise Value₹104.02
Total Cash (Recent Filing)₹6.06M
Total Debt (Recent Filing)₹10.05M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding8,131,392
10 Day Avg. Volume4,815
30 Day Avg. Volume4,526
Financial Highlights & Ratios
PEG Ratio1.24
Price to Book (P/B)9.31
Price to Sales (P/S)114.55
P/FCF Ratio-20.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong FY2026 Revenue GrowthA 69.5% revenue increase in FY2026 indicates meaningful demand or market traction. Over the next 2–6 months this revenue base can support scale economics and product adoption if cost structure is addressed, improving prospects for margin recovery and operational leverage.
Free Cash Flow ImprovementReaching break-even free cash flow is a durable operational milestone: it reflects better capex and working-capital management and extends runway versus prior cash burn. If sustained, it reduces near-term financing needs and supports longer-term strategic initiatives.
Positive Equity BufferMaintaining positive equity despite losses gives the company a structural cushion against shocks and reduces immediate insolvency risk. This equity base can help absorb further operating losses and improve the ability to negotiate credit or equity financing on reasonable terms.
Bears Say
Severe Margin DeteriorationDeep negative gross and operating margins indicate the core business is structurally unprofitable: costs far exceed revenue at the product/production level. Without sustained structural cost reductions or pricing power, revenue growth alone will not translate to durable profitability.
Persistent Negative Operating Cash FlowConsistent negative operating cash flow shows the core operations are consuming cash rather than generating it. This undermines financial resilience over months and increases reliance on external funding unless operating cash conversion and working-capital dynamics materially improve.
Rising Leverage And Debt LoadA sharp increase in leverage reduces financial flexibility and raises refinancing and solvency risk, particularly given ongoing losses. Higher debt amplifies interest obligations and limits strategic choices, making the company more vulnerable if operating results fail to recover.
Ortin Global Ltd News
ORTINGLOBE FAQ
What was Ortin Global Ltd’s price range in the past 12 months?
Ortin Global Ltd lowest stock price was ₹11.18 and its highest was ₹21.15 in the past 12 months.
What is Ortin Global Ltd’s market cap?
Ortin Global Ltd’s market cap is ₹120.51M.
When is Ortin Global Ltd’s upcoming earnings report date?
Ortin Global Ltd’s upcoming earnings report date is Aug 14, 2026 which is in 2 days.
How were Ortin Global Ltd’s earnings last quarter?
Ortin Global Ltd released its earnings results on May 30, 2026. The company reported -₹0.01 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Ortin Global Ltd overvalued?
According to Wall Street analysts Ortin Global Ltd’s price is currently Overvalued.
Does Ortin Global Ltd pay dividends?
Ortin Global Ltd does not currently pay dividends.
What is Ortin Global Ltd’s EPS estimate?
Ortin Global Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ortin Global Ltd have?
Ortin Global Ltd has 8,131,392 shares outstanding.
What happened to Ortin Global Ltd’s price movement after its last earnings report?
Ortin Global Ltd reported an EPS of -₹0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.24%.
Which hedge fund is a major shareholder of Ortin Global Ltd?
Currently, no hedge funds are holding shares in IN:ORTINGLOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ortin Global Ltd
Ortin Global Ltd., established in 1986 and headquartered in Hyderabad, India, is an Indian enterprise specializing in the manufacturing and trading of pharmaceuticals, drugs, and their intermediates. The company, formerly known as Ortin Laboratories Limited until its name change in June 2024, offers an extensive portfolio of pharmaceutical formulations available as tablets, capsules, syrups, and dry powders. These products address a wide spectrum of therapeutic areas, including anti-diabetics, anti-allergics, cardiovascular conditions, sedatives, anti-helminthics, analgesics, antipyretics, various antibiotics (quinolones, penicillins, cephalosporins, macrolides), antifungals, chemotherapeutics, antacids, anti-ulcerants, anti-spasmodics, calcium and iron supplements, anti-arthritic drugs, protein supplements, enzymes, vitamins, as well as psychiatry, appetite stimulant, gynecological, and anti-retroviral medications. Beyond finished dosage forms, Ortin Global produces active pharmaceutical ingredient (API) intermediates for anti-retroviral, anti-diabetic, analgesic, antipyretic, antibiotic, antifungal, anti-ulcerant, and anti-malarial applications. Its manufacturing capabilities also extend to fine chemicals, Grignard products, and alkali metal compounds. The company provides a range of specialized services, including process development, characterization of processes and products, analytical research and development, and assay development. It also offers R&D for new formulation brands and diagnostic services, focusing on the creation of rapid flow kits, assays, and reagents. Additionally, Ortin Global secures long-term contracts for manufacturing intermediates and developing new APIs, functions as a merchant exporter of finished pharmaceutical formulations, and holds interests in real estate.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Lasa Supergenerics Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―

